证券代码：300981 证券简称：中红医疗 公告编号：2025-091 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 科伦医械注射器 2024 年度销售收入为 6413 万元，占科伦医械 2024 年度营 业收入的 34.84%，占公司 2024 年度营业收入的 2.61%。 中红普林医疗用品股份有限公司 董事会 科伦医械上述拟中选产品的采购周期内，采购地区的医疗机构将优先使用公 司拟中选产品，并确保完成约定采购量，后续签订购销合同并实施后，将有利于 进一步扩大中选产品的市场销售，提高市场占有率，提升品牌影响力，对公司长 远发展产生积极影响。 三、风险提示 本次拟中选产品相关采购合同尚未签订，后续事项及对公司的影响程度具有 不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义务，敬请广 大投资者谨慎决策，注意投资风险。 特此公告 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加福建省漳州市一次 性使用压力 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-089 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 延续注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证》，上述注册证为原有产品的延续注册，有效期限由原 2025 年 9 月 28 日到期延续至 2030 年 9 月 28 日到期。上述注册证具体情况如下： 一、基本信息 | 注册人名称 | 产品名称 | | 注册证编号 | 注册分类 | | 注册证有效期 | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 江西科伦医 疗器械制造 | 一次性使用流 量设定微调式 | | 国械注准 | Ⅲ类 | 2025 年 | 9 月 | 29 日至 | 适 用 于 静 脉 重 力 | | | | | 20153142343 | | ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-090 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 上述医疗器械注册证的变更是在原有注册证的基础上根据实际情况进行的 相应变更。一次性使用鼻氧管领域相关产品的实际销售情况取决于未来市场的推 广效果，产品销售及利润贡献具有不确定性，目前尚无法预测上述产品对公司未 来业绩的影响，敬请相关投资者给予关注并注意投资风险。 三、备查文件 特此公告 中红普林医疗用品股份有限公司 董事会 二〇二五年九月二十九日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得江西省药品监督管理局颁发的《医疗器械变更注册 （备案）文件》。具体变更情况如下： | 产品名称 | 注册证编号 | 注册分类 | 变更内容 | 备注 | | --- | --- | --- | --- | --- | | 一次性使用鼻 氧管 | 赣械注准 20202080001 | Ⅱ类 | 生产地址由"江西省 ...

Core Insights - The article discusses the recent surge in A-share market driven by the IPO of Moore Threads, highlighting the phenomenon of "shadow stocks" where companies with minimal direct investment in the IPO are experiencing significant stock price increases [1][2][11] - It emphasizes that many companies are indirectly holding shares in Moore Threads through private equity funds, leading to a lack of substantial backing for the stock price increases [2][10] Group 1: Moore Threads IPO and Market Reaction - Moore Threads set a record with 63 working days for its IPO approval, prompting a frenzy among A-share companies to clarify their holdings in the company [1] - At least 16 A-share listed companies have responded regarding their stake in Moore Threads, with some companies like Xiamen Guomao and Crystal Electric clarifying their positions on September 25 alone [1] - The stock of Heertai surged significantly following the news of Moore Threads' IPO, reaching a peak of 60.71 CNY per share before dropping over 20% to 48.18 CNY by September 26 [3][4] Group 2: Indirect Holdings and Shadow Stocks - Many companies that have seen stock price increases related to Moore Threads have only minimal indirect holdings, often through private equity funds, such as Heertai holding approximately 1.02% directly [3][4] - Other companies like Zhongke Lanyun and Yingqu Technology hold about 0.34% each, with similar stock price volatility observed [4] - The article notes that around 70 private equity funds have participated in financing Moore Threads, with various A-share companies holding stakes through these funds [7] Group 3: Investment Trends and Market Dynamics - The trend of companies participating as limited partners (LPs) in private equity funds is common, with 195 companies investing over 21.6 billion CNY in 175 funds this year alone [9] - Historical data shows that since October 2013, 1,882 companies have invested a total of 443.41 billion CNY in 3,084 funds, with notable peaks in 2017, 2021, and 2022 [9] - The article suggests that the current "shadow stock" phenomenon is not new, as similar trends have been observed in previous market cycles, indicating a recurring pattern in A-share market behavior [11][12]

Core Viewpoint - Zhonghong Medical announced that neither the company nor its controlling subsidiaries provide guarantees to entities outside the scope of consolidated financial statements, and there are no overdue guarantees or guarantees involved in litigation [2] Summary by Relevant Sections - **Company Guarantees** - The company confirmed that it does not provide guarantees to entities outside the scope of its consolidated financial statements [2] - **Legal and Financial Status** - There are no overdue guarantees reported by the company [2] - The company is not involved in any litigation related to guarantees [2]

证券代码：300981 证券简称：中红医疗 公告编号：2025-088 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议、2024 年第三次临时 股东大会，审议通过了《关于公司及子公司 2025 年度向银行申请综合授信额度 暨公司为子公司申请综合授信额度提供担保的议案》，同意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为资产负债率 70%（含） 以上的控股子公司提供担保额度为不超过 15 亿元，为资产负债率低于 70%的控 股子公司提供担保额度为不超过 10 亿元，担保额度总计不超过 25 亿元。具体内 容详见《关于公司及子公司 2025 年度向银行申请综合授信额度暨公司为子公司 申请综合授信额度提供担保的公告》（公告编号：2024-083）。 二、担保进展情况 近日，公司全资子公司江西中红普林医疗制品有限公司 ...

Core Viewpoint - The company, Zhonghong Medical, is experiencing growth in its overseas revenue, benefiting from the depreciation of the RMB and focusing on innovative medical products for diverse market needs [4][3]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality medical and industrial disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. Group 2: Financial Performance - For the first half of 2025, Zhonghong Medical achieved a revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%, while the net profit attributable to shareholders decreased by 82.35% to 5.7429 million yuan [10]. - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11]. Group 3: Market Position and Trends - The company operates primarily through ODM direct sales, producing medical devices and consumables for overseas brand owners, which allows it to maintain a strong export focus [2]. - As of June 30, 2025, the company had a total market capitalization of 5.785 billion yuan, with a trading volume of 36.8624 million yuan on September 24, 2025 [1]. Group 4: Product Innovation and Development - Zhonghong Medical is committed to innovation, continuously launching high-performance medical products to meet diverse market demands, and integrating digital technology into product development for smart upgrades [3]. - The company showcased its veterinary infusion pumps at the 12th Beijing Pet Expo, highlighting their safety and multifunctionality, which received positive feedback from veterinary professionals [2].

Core Viewpoint - Zhonghong Medical announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd., has obtained a medical device registration certificate from the National Medical Products Administration, extending the validity of the existing product registration until February 28, 2031 [1] Group 1 - The registration certificate is a continuation of the existing product registration [1] - The previous expiration date of the registration was February 28, 2026 [1] - The new effective period extends the registration by five years [1]

证券代码：300981 证券简称：中红医疗 公告编号：2025-087 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 延续注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证》，上述注册证为原有产品的延续注册，有效期限由原 2026 年 2 月 28 日到期延续至 2031 年 2 月 28 日到期。上述注册证具体情况如下： 一、基本信息 特此公告 中红普林医疗用品股份有限公司 二、对公司的影响及风险提示 上述医疗器械注册证有效期的延长，延续了公司及子公司在一次性使用输液 用肝素帽领域的产品品类，能够保证原有产品的持续销售，并将进一步增强公司 及子公司的综合竞争力，不断满足多元化的市场需求，有利于进一步提高市场拓 展能力。 上述产品实际销售情况取决于未来市场的推广效果，产品销售及利润贡献具 有不确定性，目前尚无法预测上述产品对公司未来业绩的影响，敬请投资者注意 防范投资 ...

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model, which allows it to design and produce products for overseas brand owners [2][4]. Group 1: Company Overview - Zhonghong Medical is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The company was established on December 22, 2010, and went public on April 27, 2021. Its main business includes the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves [9]. - As of June 30, 2025, the company had 20,200 shareholders, with an average of 19,502 circulating shares per person, reflecting a 0.40% increase in shareholder numbers [10]. Group 2: Financial Performance - For the first half of 2025, Zhonghong Medical achieved a revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%. However, the net profit attributable to shareholders decreased by 82.35% to 5.7429 million yuan [10]. - The company's overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Product and Market Development - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which received positive feedback for their safety and multifunctionality [2]. - The company emphasizes innovation and digital technology integration in product development, aiming to become a leading provider of intelligent medical solutions [3]. Group 4: Market Activity - On September 23, Zhonghong Medical's stock fell by 1.76%, with a trading volume of 80.3791 million yuan and a turnover rate of 1.54%, resulting in a total market capitalization of 5.73 billion yuan [1]. - The average trading cost of the stock is 14.67 yuan, with the current price approaching a resistance level of 13.54 yuan, indicating potential for upward movement if this level is surpassed [8].